A5063153537- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Venous Thromboembolism Diagnosis and Management
- Cutaneous lymphoproliferative disorders research
- T-cell and Retrovirus Studies
- Polyomavirus and related diseases
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Acute Lymphoblastic Leukemia research
- Cancer Risks and Factors
- Cancer Immunotherapy and Biomarkers
- Health Systems, Economic Evaluations, Quality of Life
- Nutrition and Health in Aging
- Prostate Cancer Treatment and Research
- Metabolism, Diabetes, and Cancer
- Peptidase Inhibition and Analysis
- Multiple and Secondary Primary Cancers
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Childhood Cancer Survivors' Quality of Life
- Histone Deacetylase Inhibitors Research
Northwestern University
2004-2025
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2005-2025
University of South Carolina
2022-2024
City of Hope
2024
Washington University in St. Louis
2014-2023
Rush University
2020-2023
Tempus Labs (United States)
2020-2022
Rush University Medical Center
2020-2022
St. Louis VA Medical Center
2012-2021
Flatiron Health (United States)
2017-2021
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with multiple myeloma (MM). The International Myeloma Working Group (IMWG) developed guidelines recommending primary thromboprophylaxis, in those identified at high-risk VTE by the presence risk factors. National Comprehensive Cancer Network (NCCN) has adopted these guidelines; however, they lack validation. We sought to develop validate prediction score for MM evaluate performance current IMWG/NCCN...
BACKGROUND Brentuximab vedotin (BV) is an anti‐CD30 monoclonal antibody‐drug conjugate that was approved in 2011 for the treatment of patients with anaplastic large cell and Hodgkin lymphomas. The product label indicates 3 who were treated BV developed progressive multifocal leukoencephalopathy (PML), a frequently fatal JC virus‐induced central nervous system infection. Prior immunosuppressive therapy compromised immune systems postulated risk factors. In current study, authors reported 5...
Tumor mutational burden (TMB) is a potential biomarker associated with response to immune checkpoint inhibitor therapies. The prognostic value TMB in the absence of immunotherapy uncertain.To assess prevalence high (TMB-H) and its association overall survival (OS) among patients not treated same 10 tumor types from KEYNOTE-158 study.This retrospective cohort study evaluated TMB-H, assessed by Foundation Medicine (FMI) defined as at least mutations/megabase (mut/Mb) immunotherapy. Data were...
Background The role of autologous stem cell transplantation (ASCT) in the first complete remission (CR1) peripheral T‐cell lymphomas (PTCLs) is not well defined. This study analyzed impact ASCT on clinical outcomes patients with newly diagnosed PTCL CR1. Methods Patients diagnosed, histologically confirmed, aggressive were prospectively enrolled into Comprehensive Oncology Measures for Peripheral T‐Cell Lymphoma Treatment (COMPLETE) study, and those CR1 included this analysis. Results Two...
The US Food and Drug Administration (FDA) is increasing its pace of approvals for novel cancer therapeutics, including immune checkpoint inhibitors programmed cell death 1 protein (anti-PD-1 agents). However, little known about how quickly anti-PD-1 agents reach eligible patients in practice or whether such differ from those studied clinical trials that lead to FDA approval (pivotal trials).
Purpose The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) have activity in one of the pathways influenced by nitrogen-containing bisphosphonates, which are associated with improved survival multiple myeloma (MM). To understand benefit statins MM, we evaluated association between statin use and mortality a large cohort patients MM. Patients Methods From Veterans Administration Central Cancer Registry, identified diagnosed MM 1999 2013. We defined as presence any...
In 1998, a multidisciplinary team of investigators initiated RADAR (Research on Adverse Drug events And Reports), clinically based postmarketing surveillance program that systematically investigates and disseminates information describing serious previously unrecognized adverse drug device reactions (ADRs).To describe the structure, operations, preliminary findings from project related dissemination efforts by pharmaceutical suppliers US Food Administration (FDA).After identifying unexpected...
High-dose methotrexate (HDMTX), defined by doses of (MTX) ≥ 1 g/m2, is a widely used regimen known to cause renal toxicity. The reported incidence toxicity in patients with osteosarcoma 1.8%, but the hematologic malignancies not well characterized. In this retrospective study 649 cycles HDMTX 194 patients, occurred 9.1% lymphoma compared 1.5% sarcoma. Older age, male sex, decreased baseline creatinine clearance (CrCl) and increased proton pump inhibitor use among population likely...
Obesity increases the risk of death from many malignancies, including non-Hodgkin's lymphoma (NHL). In diffuse large B-cell (DLBCL), most common form NHL, association between body mass index (BMI) at diagnosis and survival is unclear.We evaluated BMI overall in a retrospective cohort 2,534 United States veterans diagnosed with DLBCL October 1, 1998 December 31, 2008. Cox modeling was used to control for patient- disease-related prognostic variables.Mean age 68 years (range, 20 100 years);...
Peripheral T-cell lymphomas (PTCL) have suboptimal outcomes using conventional CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. The anti-folate pralatrexate, the first drug approved for patients with relapsed/refractory PTCL, provided a rationale to incorporate it into front-line setting. This phase 2 study evaluated novel combination whereby cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternated pralatrexate (CEOP-P) in PTCL. Patients achieving...
Abstract Choosing Wisely® is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading societies United States. The ASH an active participant project. Using iterative process evidence-based method, has identified 5 tests treatments that some circumstances are not well supported evidence which certain cases involve risk adverse events financial costs low likelihood benefit. recommendations focus on avoiding...
Multiple myeloma (MM) is one of the most common hematologic malignancies in United States and consistently preceded by monoclonal gammopathy undetermined significance (MGUS). This study investigates role obesity progression MGUS to MM.A retrospective identified cohort patients US Veterans Health Administration database diagnosed with between October 1, 1999, December 31, 2009, was followed through August 6, 2013. Patient-level clinical data were reviewed verify MM diagnosis, if any. Survival...
Evidence from cancer clinical trials has strong internal validity but can be difficult to generalize real-world patient populations. Here we analyzed outcomes of patients with metastatic non-small cell lung (mNSCLC) treated programmed death protein 1 (PD-1) inhibitors in the first year following U.S. regulatory approval.This retrospective study leveraged electronic health record (EHR) data collected during routine care community clinics. The cohort included mNSCLC who had received nivolumab...
BACKGROUND Long‐term survival in patients with aggressive peripheral T‐cell lymphoma (PTCL) is generally poor, and there currently no clear consensus regarding the initial therapy used for these diseases. Herein, authors analyzed treatment patterns outcomes a prospectively collected cohort of new diagnosis nodal PTCL United States. METHODS Comprehensive Oncology Measures Peripheral Lymphoma Treatment (COMPLETE) prospective multicenter study designed to identify most common prevailing newly...